Skip to content
Educational information only. Not medical advice. We sell nothing and take no affiliate money.
By /
PeptideMostly animalNot FDA approved

Bronchogen

Four amino acid peptide (alanine, glutamic acid, aspartic acid, leucine)

Last reviewed October 27, 2026 · 19 sources · Written for general readers · Compare with another compound →

The bottom line

Bronchogen is a four amino acid peptide from the Khavinson group, sold online for lung health.[1] It has been tested in lung cells and in rats with lung injury, but never in published human trials.[2][3] Even its exact sequence is written two different ways in the group's own papers.[1][4]

Where the evidence stands

What it is

Bronchogen is a tiny peptide made of four amino acids: alanine, glutamic acid, aspartic acid and leucine. It comes from the short peptide program of Vladimir Khavinson in St. Petersburg.[1]

The order of the amino acids is not consistent across the group's own papers. Some, and the US patent, list it as AEDL[1][13][8] while others list it as ADEL, with the middle two swapped.[4][10] Because of this, we leave the sequence field blank.

It is sold for COPD, asthma, bronchitis and lungs damaged by smoking. The sections below check each claim against the published studies.

Name
Bronchogen (Four amino acid peptide (alanine, glutamic acid, aspartic acid, leucine))
Other names
AEDL, ADEL
Type
Peptide

What it does in the body

Bronchogen is not a natural hormone. It is a lab made chain of four amino acids that the developer's group links to airway tissue and says works by entering cells and binding DNA to change which genes are active.[1][3] In a dish it entered the cell nucleus,[5] but no target in the living body has been confirmed.

This is the biology, area by area. A change measured in the body, like a higher blood level, does not always mean a person feels a benefit. The claims check below covers that.

Airway lining cells

Lab finding

In human airway cells grown in a dish at early, middle and late stages of aging, it raised Ki67, a marker of dividing cells, and Mcl1, a survival protein, most in old cultures, and switched on genes for mucus and surfactant, the film that keeps air sacs open.[4] In aging airway cell cultures it also raised markers of cell maturity, with a bigger effect in older cultures.[6]

Lungs in disease models

Seen in animals

In rats given a COPD like disease by breathing nitrogen dioxide for 60 days, one month of Bronchogen reversed extra mucus cells and emphysema, the breakdown of air sacs, and restored the hair covered cells that sweep out mucus.[2] A follow up by the same team reported less inflammation and more surfactant protein B.[7] The inventors' patent describes faster recovery in rats with bacterial lung infection and less scarring in rats with drug induced lung fibrosis, but patent data are not peer reviewed.[8]

Immune defense in the airways

Seen in animals

In the rat COPD model, Bronchogen raised secretory IgA, an antibody that guards the airway lining, and brought inflammatory cells and signals in lung fluid back toward normal.[2][7] In the patent's lung scarring model, lung fluid held roughly a quarter to a third as many lymphocytes, a type of white blood cell, as in untreated rats at days 30 and 60, but these patent data are not peer reviewed.[8]

Heart strain from lung disease

Seen in animals

In the patent's rat lung fibrosis model, a measure of right heart enlargement, which happens when damaged lungs make the heart pump harder, was about 47% in treated rats versus 66% in untreated rats at day 60.[8] This has not been published in a peer reviewed journal.

DNA and genes

Lab finding

In test tube work it bound DNA, preferred certain short DNA letter patterns, bound histones, the proteins DNA wraps around, and slightly raised the heat needed to melt DNA apart, by about 3.1 degrees Celsius.[5][9][10] The group also reported that its effects on chemical tags on airway genes depended on the tissue and the age of the cells.[11]

Getting into cells

Lab finding

Labeled Bronchogen entered the nucleus of human cancer cells in a dish.[5] A computer modeling study predicted it is among the peptides most likely to be carried into cells by known transporter proteins, but this was not measured in living tissue.[12]

How it works

The group says Bronchogen acts directly on genes in airway lining cells.

  • In human airway cells grown in a dish, the peptide changed levels of proteins tied to cell growth and cell death, and raised genes linked to airway cell maturity and mucus.[4]
  • The group also studied chemical tags on DNA (methylation) that turn airway genes up or down with age, and reported that the peptide's effects on these genes depended on the tissue and the age of the cells.[11]
  • Lab tests suggested it binds DNA, prefers certain short DNA letter patterns, and slightly raised the heat needed to melt DNA apart, by about 3.1 degrees Celsius.[5][10]
  • A computer modeling study predicted it is among the peptides most likely to be carried into cells by known transporter proteins.[12]

This is a lab based theory from the developer's group and has not been proven in living people.

What the research shows

We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.

Animal and lab studies

Lung cell studies, rat lung disease studies and patent data

  • In aging cultures of human embryo airway cells, it raised markers of cell maturity, with a bigger effect in older cultures.[6]
  • In human airway cells at early, middle and late stages of aging in a dish, it raised the growth marker Ki67 and the survival protein Mcl1 most in old cultures, and switched on mucus and surfactant genes.[4]
  • In rats given a COPD like disease by breathing nitrogen dioxide for 60 days, one month of Bronchogen reduced airway damage and inflammation and raised a local immune antibody.[2]
  • A follow up study by the same rat team reported less inflammation in lung fluid, more surfactant protein B and repair of the airway lining.[7]
  • The inventors' patent describes three more rat models: a staph lung infection in 120 rats, lung scarring from bleomycin in 120 rats, and lung injury from breathing pure oxygen in 96 rats. It reports faster recovery of immune cells, less scarring and better lung structure, plus 90 day and 6 month toxicity tests in rats and guinea pigs that the authors say showed no toxic effects.[8]
  • In lung tissue from young and old rats grown in a dish, Bronchogen and sister peptides boosted growth of their matching tissue.[14]
  • The journal rat studies came from a St. Petersburg lung institute team that did not list Khavinson as an author, but the English summaries give no numbers.[2][7]

Limit: These are small cell and rat studies in Russian or translated journals, plus patent data that were never peer reviewed, with no outside replication.

Human studies

No human studies

  • We found no published clinical trials of Bronchogen in people. The group's reviews describe cell, plant and animal work, not human results.[15][3]
  • The US patent describes only animal and lab work and suggests clinical studies as a next step.[8]

Limit: Without human trials, there is no evidence it helps lungs in people or that it is safe to use.

Claims check

The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.

Repairs lungs in COPD and chronic bronchitis

Only in animals

In rats given a COPD like disease by breathing nitrogen dioxide for 60 days, one month of Bronchogen reversed signs of airway damage, including extra mucus making cells and emphysema, the breakdown of air sacs, and restored the cells with tiny hairs that clear mucus.[2] A follow up rat study by the same team reported less inflammation and more surfactant protein B, which helps keep air sacs open.[7] No human trial exists.

Reduces lung scarring

Only in animals

The inventors' patent reports that in 120 rats with lung scarring caused by the drug bleomycin, treatment reduced but did not prevent fibrosis and eased strain on the right side of the heart.[8] These results were not published in a peer reviewed journal, and no human study exists.

Eases asthma

Not tested

No study we found tested Bronchogen for asthma, in animals or people. The living animal studies used COPD like, infection, scarring and high oxygen models in rats.[2][8]

Heals lungs damaged by smoking

Not tested

No study we found tested Bronchogen against smoke damage. The rat studies used nitrogen dioxide, an air pollutant, to injure the lungs, which is not the same as years of cigarette smoke.[2]

Boosts lung immunity

Only in animals

In the rat COPD model, Bronchogen raised secretory IgA, an antibody that guards the airway lining, and brought inflammatory cells and signals in lung fluid back toward normal.[2][7] In the patent's rat infection model, immune cells in the air sacs recovered faster, but no exact numbers were given and patent data are not peer reviewed.[8]

Slows lung aging

Only in animals

In aging cultures of human embryo airway cells, the peptide raised markers of cell maturity, with a bigger effect in older cultures.[6] Its strongest effect on cell growth markers was also in old cultures.[4] These are dish studies only.

Known risks and side effects

  • Unregulated products. It is sold online outside pharmacies with no FDA review, so what is in the vial or capsule, how pure it is, and how much it holds are unknown.[16]
  • Unclear identity. The group's papers give two different amino acid orders for this peptide, so a product label may not match what was studied.[1][4]
  • No human safety data. No human trials have been published, so side effects and how often they happen are unknown. The only safety data are the patent's animal toxicity tests.[3][8]
  • Delaying real care. COPD and asthma have treatments proven in large trials. The peptide has only rat data, so it should not replace them.[2]
  • Banned in sport. World Anti Doping Agency rules ban, at all times, substances with no current approval for human use, and the 2027 list now names peptides among its examples.[17][18]

Regulatory status

Today: It is not approved by the FDA for any use. It is not named on FDA's list of risky bulk substances for compounding as updated April 22, 2026, and it is not one of the peptides in the October 28, 2026 HHS interim compounding policy, which covers six other peptides.[16][19] The World Anti Doping Agency bans at all times any substance with no current government approval for human use, so athletes should treat it as banned. The 2027 list, in force January 1, 2027, adds peptides to the examples it gives for this group.[17][18]

  1. A US patent was granted to Khavinson and coworkers for the AEDL peptide as a substance that restores lung function, based on rat studies.[8]
  2. The 2027 World Anti Doping Agency list takes effect and names peptides as an example of banned unapproved substances.[18]

Sources

  1. Khavinson VKh, Lin'kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288-292. PMID 27909961
  2. Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015;159(5):685-8. PMID 26468022
  3. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMC8619776
  4. Khavinson VK, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-91. PMID 25015171
  5. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-9. PMID 22117547
  6. Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-51. PMID 22808515
  7. Titova ON, Kuzubova NA, Lebedeva ES, Preobrazhenskaya TN, Surkova EA, Dvorakovskaya IV. [Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology]. Ross Fiziol Zh Im I M Sechenova. 2017;103(2):201-8. PMID 30199201
  8. Khavinson VK, Ryzhak GA, Grigoriev EI, Ryadnova IY. Peptide substance restoring respiratory organs function. US Patent 7,625,870 B2. Granted December 1, 2009. US 7625870 B2
  9. Fedoreyeva LI, Smirnova TA, Kolomijtseva GY, Khavinson VKh, Vanyushin BF. Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides. Biochemistry (Mosc). 2013;78(2):166-75. PMID 23581987
  10. Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375-7. PMID 21240358
  11. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Mosc). 2015;80(3):310-22. PMID 25761685
  12. Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023;13(3):552. PMID 36979488
  13. Fedoreyeva LI, Dilovarova TA, Ashapkin VV, Martirosyan YuTs, Khavinson VKh, Kharchenko PN, Vanyushin BF. Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum. Biochemistry (Mosc). 2017;82(4):521-528. PMID 28371610
  14. Zakutskii AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN. [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]. Adv Gerontol. 2006;19:93-6. PMID 17152728
  15. Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Rev Rep. 2020;16(1):118-125. PMID 31808038
  16. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. FDA
  17. World Anti-Doping Agency. The 2026 Prohibited List, World Anti-Doping Code International Standard. In force January 1, 2026. WADA 2026
  18. World Anti-Doping Agency. The 2027 Prohibited List, World Anti-Doping Code International Standard. In force January 1, 2027. WADA 2027
  19. U.S. Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register document 2026-22192. Filed October 28, 2026; publication date October 30, 2026. FR 2026-22192
Medical disclaimer

This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.

Found an error or a newer study? We correct pages fast.

Report a correction →
Scroll to Top